PL EN


Preferences help
enabled [disable] Abstract
Number of results
2019 | 117 | 137-146
Article title

The role of vasopressin in the activity of the central nervous system and in the pathogenesis and therapy of schizophrenia

Content
Title variants
Languages of publication
EN
Abstracts
EN
Vasopressin - pituitary neurohormone, in addition to the essential role of which is to regulate blood pressure and affecting the body's water balance, it is involved in other processes such as social behaviour, memory processes and learning. It also plays an important role in modulating anxiety. This hormone seems indispensable for the creation of proper social interactions, and its low plasma levels correlate with the dysfunction of interpersonal relationships. In this article, we review and summarize the studies on the role of vasopressin in the pathogenesis and therapy of schizophrenia. Despite some potential limitations in peer-reviewed studies, the literature suggests the potential role of vasopressin in the pathogenesis of schizophrenia and the possible therapeutic application in this psychiatric disorder.
Discipline
Year
Volume
117
Pages
137-146
Physical description
Contributors
  • Student Science Club at the Department of Applied Psychology, Medical University of Lublin, Lublin, Poland
author
  • Student Science Club at the Department of Applied Psychology, Medical University of Lublin, Lublin, Poland
  • Student Science Club at the Department of Applied Psychology, Medical University of Lublin, Lublin, Poland
  • Student Science Club at the Department of Applied Psychology, Medical University of Lublin, Lublin, Poland
  • Department of Applied Psychology, Medical University of Lublin, Lublin, Poland
  • Department of Applied Psychology, Medical University of Lublin, Lublin, Poland
References
  • [1] C. Gizowski, E. Trudel, C.W. Bourque. Central and peripheral roles of vasopressin in the circadian defense of body hydration. Best Pract Res Clin Endocrinol Metab. 31(6) (2017) 535-546.
  • [2] V. Bugaj, O. Pochynyuk, J.D. Stockand. Activation of the epithelial Na+ channel in the collecting duct by vasopressin contributes to water reabsorption. Am J Physiol Renal Physiol. 297(5) (2009) 1411-8.
  • [3] K.L. Byron. Vasopressin stimulates Ca2+ spiking activity in A7r5 vascular smooth muscle cells via activation of phospholipase A2. Circ Res. 78(5) (1996) 813-20.
  • [4] P.H. Baylis. Regulation of vasopressin secretion. Baillieres Clin Endocrinol Metab. 3(2) (1989) 313-30.
  • [5] J.L. Vincent, F. Su. Physiology and pathophysiology of the vasopressinergic system. Best Pract Res Clin Anaesthesiol. 22(2) (2008) 243-52.
  • [6] X.J. Shou, X.J. Xu, X.Z. Zeng, et al. Volumetric and Functional Connectivity MRI Study of Brain Arginine-Vasopressin Pathways in Autistic Children. Neurosci Bull. 33(2) (2017) 130-142.
  • [7] R.L. Narang, R.R. Chaudhury, N.N. Wing. Effect of electroconvulsive therapy on the antidiuretic hormone level in the plasma of schizophrenic patients. Indian J Med Res. 61(5) (1973) 766-70.
  • [8] C.S. Carter. The Role of Oxytocin and Vasopressin in Attachment. Psychodyn Psychiatry. 45(4) (2017) 499-517.
  • [9] L.H. Rubin, L. Yao, S.K. Keedy, et al. Sex differences in associations of arginine vasopressin and oxytocin with resting-state functional brain connectivity. J Neurosci Res. 95(1-2) (2017) 576-586.
  • [10] C.N. Yohn, A.B. Leithead, E.A. Becker. Increased vasopressin expression in the BNST accompanies paternally induced territoriality in male and female California mouse offspring. Horm Behav. 93 (2017) 9-17.
  • [11] J.I. Terranova, Z. Song, T.E. Larkin, et al. Serotonin and arginine-vasopressin mediate sex differences in the regulation of dominance and aggression by the social brain. Proc Natl Acad Sci U S A. 113(46) (2016) 13233-13238.
  • [12] Galbusera, A. De Felice, S. Girardi, et al. Intranasal Oxytocin and Vasopressin Modulate Divergent Brainwide Functional Substrates. Neuropsychopharmacology. 42(7) (2017) 1420-1434.
  • [13] P. Csikota, A. Fodor, D, Balazsfi, et al. Vasopressinergic control of stress-related behavior: studies in Brattlebororats. Stress. 19(4) (2016) 349-61.
  • [14] I.F. Bielsky, S.B. Hu, X. Ren, et al. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. Neuron. 47(4) (2005) 503-13.
  • [15] M. Gozzi, E.M. Dashow, A. Thurm, et al. Effects of Oxytocin and Vasopressin on Preferential Brain Responses to Negative Social Feedback. Neuropsychopharmacology. 42(7) (2017) 1409-1419.
  • [16] C. Yang, X. Zhang, J. Gao, et al. Arginine vasopressin ameliorates spatial learning impairments in chronic cerebral hypoperfusion via V1a receptor and autophagy signaling partially. Transl Psychiatry. 7(7) (2017) e1174.
  • [17] M. Le Moal, R. Dantzer, B. Michuad, et al. Centrally injected arginine vasopressin (AVP) facilitates social memory in rats. Neurosci Lett. 77(3) (1987) 353-9.
  • [18] A.J. Guastella, A.R. Kenyon, G.A. Alvares, et al.Intranasal arginine vasopressin enhances the encoding of happy and angry faces in humans. Biol Psychiatry. 67(12) (2010) 1220-2.
  • [19] C.F. Zink, L. Kempf, S. Hakimi, et al. Vasopressin modulates social recognition-related activity in the left temporoparietal junction in humans. Transl Psychiatry. 1(4) (2011) e3.
  • [20] K. Demeter, B. Torok, A. Fodor, et al. Possible contribution of epigenetic changes in the development of schizophrenia-like behavior in vasopressin-deficient Brattleboro rats. Behav Brain Res. 300(1) (2016) 123-34.
  • [21] M.C. Ryan, N. Sharifi, R. Condren, et al. Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology. 29(8) (2004) 1065-70.
  • [22] C.E. Marx, J.A. Lieberman. Psychoneuroendocrinology of schizophrenia. Psychiatr Clin North Am. 21(2) (1998) 413-34.
  • [23] H. Obsawa, T. Kishimoto, N. Shimayoshi, et al. Atrial natriuretic peptide and arginine vasopressin secretion in schizophrenic patients. Acta Psychiatr Scand. 88(2) (1993) 130-4.
  • [24] Kudoh, M. Kudo, H. Ishihara, et al. Increased plasma vasopressin and atrial natriuretic peptide in chronic schizophrenic patients during abdominal surgery. Neuropsychobiology. 37(4) (1998) 169-74.
  • [25] M. Sarai, H. Matsunaga. ADH secretion in schizophrenic patients on antipsychotic drugs. Biol Psychiatry. 26(6) (1989) 576-80.
  • [26] L.H. Rubin, C.S. Carter, J.R. Bishop, et al. Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr Bull. 40(6) (2014) 1374-84.
  • [27] Y. Edoute, M.R. Davids, C. Johnston, et al. An integrative physiological approach to polyuria and hyponatraemia: a 'double-take' on the diagnosis and therapy in a patient with schizophrenia. QJM. 96(7) (2003) 531-40.
  • [28] S.L. Dubovsky, S. Grabson, T. Berl, et al. Syndrome of inappropriate secretion of antidiuretic hormone with exacerbated psychosis. Ann Intern Med. 79(4) (1973) 551-4.
  • [29] M. Kushnir, A. Schattner, T. Ezri, et al. Schizophrenia and fatal self-induced water intoxication with appropriately-diluted urine. Am J Med Sci. 300(6) (1990) 385-7.
  • [30] Y.I. Malidelis, M.T. Panayotacopoulou, J.J. van Heerikhuize, et al. Absence of a difference in the neurosecretory activity of supraoptic nucleus vasopressin neurons of neuroleptic-treated schizophrenic patients. Neuroendocrinology. 82(2) (2005) 63-9.
  • [31] Jobst, S. Dehning, T. Notz, Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients. Acta Neuropsychiatr. 26(6) (2014) 347-55.
  • [32] O. Teltsh, K. Kanyas-Sarne, A. Rigbi, et al. Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree. Int J Neuropsychopharmacol. 15(3) (2012) 309-19.
  • [33] V.D. Bakharev, S.M. Tikhomirov, O.S. Papsuevich, et al. Use of vasopressin the treatment of the paranoid form of schizophrenia. Zh Nevropatol Psikhiatr Im S S Korsakova. 84(1) (1984) 88-92.
  • [34] A.C. Iager, D.G. Kirch, L.B. Bigelow, et al. Treatment of schizophrenia with a vasopressin analogue. Am J Psychiatry. 143(3) (1986) 375-7.
  • [35] F. Brambilla, G.P. Bondiolotti, M. Maggioni, et al. Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory. Neuropsychobiology. 20(3) (1989) 113-9.
  • [36] S.M. Hosseini, M. Farokhnia, F. Rezaei, et al. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. Eur Neuropsychopharmacol. 24(6) (2014) 846-55.
  • [37] C.H. Geng, C. Wang, J. Yang, et al. Arginine vasopressin improves the memory deficits in Han Chinese patients with first-episode schizophrenia. Peptides. 97 (2017) 8-15.
  • [38] T. Matsuoka, T. Sumiyoshi, K. Tanaka, et al. NC-1900, an arginine-vasopressin analogue, ameliorates social behavior deficits and hyperlocomotion in MK-801-treated rats: therapeutic implications for schizophrenia. Brain Res. 1053 (2005) 131-6.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-096253ef-5f34-488e-8e40-979e9f6b7f8c
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.